Wegovy weight loss chart: STEP and OASIS trial results
In STEP 1, the main 68-week trial in 1,961 adults without diabetes, average weight changed −14.9% with Wegovy 2.4 mg injection vs −2.4% with placebo, as reported in the FDA label. The higher 7.2 mg injection (Wegovy HD) reached −18.8% in the 72-week STEP UP trial, and the once-daily 25 mg tablet −13.6% at 64 weeks in OASIS 4. These are trial averages from different trials and formulations and do not predict any one person’s result.
Checked against the FDA label and cited trials on
Peptide Library is an independent educational resource. It is not affiliated with, sponsored or endorsed by Novo Nordisk or Eli Lilly; Ozempic, Wegovy, Mounjaro and Zepbound are trademarks of their owners and are named only to identify the products. This page summarizes FDA-approved prescribing information and published trials. It is not individual medical advice: dosing and any change to it are decided with a prescriber.
The product
Wegovy (semaglutide)
Manufacturer
Novo Nordisk
Form
Once-weekly injection (single-dose pens and syringes, FlexTouch pen; 7.2 mg as Wegovy HD) or once-daily tablets
FDA-approved uses
Reducing excess body weight and keeping it off long term in adults with obesity, or overweight with a weight-related condition, and in children 12 and older with obesity (injection)
Reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight
Noncirrhotic MASH with moderate to advanced liver fibrosis in adults (injection; accelerated approval)
Boxed warning
Risk of thyroid C-cell tumors: semaglutide caused thyroid C-cell tumors in rodents; whether it does in humans is unknown. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Group averages from selected trial populations, each beside its own trial’s comparator. They do not predict any one person’s result, and figures from different trials are not compared with each other.
Adults with obesity, or overweight with a weight-related condition, without type 2 diabetes
Randomized
1,961
Duration
68 weeks
Comparator
Placebo
Reported results
STEP 1 (injection 2.4 mg): Mean % change in body weight, Week 68Label section 14: all randomized patients, missing data imputed from retrieved dropouts
STEP 1 (injection 2.4 mg): Mean % change in body weight at Week 68, by arm
The publication (Wilding 2021) reports the same means with a slightly different confidence interval and share reaching 5%, from a different analysis; this page uses the label.
STEP 2 (injection 2.4 mg, type 2 diabetes): Mean % change in body weight, Week 68Label section 14: all randomized patients, missing data imputed from retrieved dropouts
STEP 2 (injection 2.4 mg, type 2 diabetes): Mean % change in body weight at Week 68, by arm
Adults with obesity or overweight, with intensive behavioral therapy and an initial 8-week low-calorie diet
Randomized
611
Duration
68 weeks
Comparator
Placebo
Reported results
STEP 3 (injection 2.4 mg with intensive behavioral therapy): Mean % change in body weight, Week 68Label section 14: all randomized patients, missing data imputed from retrieved dropouts
STEP 3 (injection 2.4 mg with intensive behavioral therapy): Mean % change in body weight at Week 68, by arm
Adults who completed a 20-week run-in on Wegovy, then were randomized to continue or switch to placebo
Randomized
803
Duration
Week 20 to week 68
Comparator
Placebo (treatment withdrawn)
Reported results
STEP 4 (stopping vs continuing): Mean % change in body weight from week 20, Week 68Label section 14: all randomized patients, missing data imputed from retrieved dropouts
STEP 4 (stopping vs continuing): Mean % change in body weight from week 20 at Week 68, by arm
Adults with obesity (BMI ≥30) without type 2 diabetes
Randomized
1,407
Duration
72 weeks
Comparator
Placebo and Wegovy 2.4 mg
Reported results
STEP UP (injection 7.2 mg, Wegovy HD): Mean % change in body weight, Week 72Label section 14: all randomized patients, missing data imputed from retrieved dropouts
STEP UP (injection 7.2 mg, Wegovy HD): Mean % change in body weight at Week 72, by arm
STEP UP (injection 7.2 mg, Wegovy HD): adverse events by arm
Event
7.2 mg
2.4 mg
Placebo
Dysesthesia (altered skin sensation)
22%
6%
0%
Percent of participants, as reported in Wegovy (semaglutide) injection and tablets prescribing information, DailyMed, effective 2026-06-18.
Approved 2026-03-19 for adults who tolerated 2.4 mg for at least 4 weeks and need more weight reduction. FDA said it is investigating the altered-skin-sensation reports further.
The publication (Lancet Diabetes Endocrinol 2025) gives −18.7% and −15.6% from its own analysis; this page uses the label.
STEP UP T2D (injection 7.2 mg, type 2 diabetes): Mean % change in body weight, Week 72Label section 14: all randomized patients, missing data imputed from retrieved dropouts
STEP UP T2D (injection 7.2 mg, type 2 diabetes): Mean % change in body weight at Week 72, by arm
Adults with obesity, or overweight with a weight-related condition, without diabetes
Randomized
304
Duration
104 weeks
Comparator
Placebo
Reported results
STEP 5 (injection 2.4 mg, two years): Mean % change in body weight, Week 104Treatment-policy analysis, all randomized participants (publication; not in the label)
STEP 5 (injection 2.4 mg, two years): Mean % change in body weight at Week 104, by arm
Wegovy is semaglutide as a once-weekly injection (maintenance 1.7 or 2.4 mg, or up to 7.2 mg as Wegovy HD for adults who tolerated 2.4 mg for at least 4 weeks) and, since 2025-12-22, as a once-daily tablet (25 mg maintenance). Each panel names the formulation and dose studied. Trials differ in population and length, so figures are not compared across panels.
Numbers are the label’s least-squares means for all randomized patients, missing data imputed from retrieved dropouts. STEP 5 is not in the label and comes from its publication.
Heart outcomes: SELECT
In SELECT (17,604 adults aged 45 or older with cardiovascular disease and BMI ≥27, without diabetes, median follow-up 41.8 months), major cardiovascular events occurred in 6.5% on Wegovy vs 8% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90). This is the basis of Wegovy’s cardiovascular indication, approved 2024-03-08.
Side effects in the label
In the pooled 2.4 mg trials (up to 68 weeks), nausea was reported in 44% vs 16% on placebo, diarrhea 30% vs 16%, vomiting 24% vs 6% and constipation 24% vs 11%; 6.8% stopped because of adverse reactions vs 3.2%. With 7.2 mg, altered skin sensation (dysesthesia) was reported in 22% vs 6% on 2.4 mg.
Questions
How much weight do people lose on Wegovy?
+
In STEP 1 the average change at 68 weeks was −14.9% with 2.4 mg vs −2.4% with placebo, per the label. Results vary widely between people and averages do not predict any one person’s.
Is the Wegovy pill as effective as the injection?
+
They were tested in different trials. The 25 mg tablet reached −13.6% vs −2.4% with placebo over 64 weeks (OASIS 4); the 2.4 mg injection −14.9% vs −2.4% over 68 weeks (STEP 1). No conclusion about relative effect follows from separate trials.
What is Wegovy HD?
+
The 7.2 mg once-weekly injection, approved 2026-03-19 for adults who tolerated 2.4 mg for at least 4 weeks and need more weight reduction. In STEP UP it reached −18.8% vs −15.5% with 2.4 mg and −3.9% with placebo over 72 weeks.
Peptide Library